In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Acorda Therapeutics (NASDAQ: ACOR), with a price target of $30. The company’s shares opened today at $22.50.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 12.2% and a 51.0% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Voyager Therapeutics Inc, and Adverum Biotechnologies.
Acorda Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $28.
See today’s analyst top recommended stocks >>
The company has a one-year high of $29.60 and a one-year low of $13.60. Currently, Acorda Therapeutics has an average volume of 499.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Acorda Therapeutics, Inc. develops and markets therapeutic products for nervous system disorders. The company’s two main products are Ampyra and Zanaflex Capsules.
